ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Vicky Makker; Ignace Vergote; Mansoor Mirza; Robert Coleman; Jose Alejandro Perez Fidalgo; Bradley Monk; Giorgio Valabrega; Brian Slomovitz; Toon van Gorp; Kathleen Moore; Jalid Sehouli; David Cibula; Tally Levy; Gerasimos Aravantinos; Patricia Judson; Reshma Rangwala; Xulong Wang

doi:10.1016/j.ygyno.2023.06.155

Back

ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Journal article

Peer reviewed

ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Vicky Makker, Ignace Vergote, Mansoor Mirza, Robert Coleman, Jose Alejandro Perez Fidalgo, Bradley Monk, Giorgio Valabrega, Brian Slomovitz, Toon van Gorp, Kathleen Moore, …

Gynecologic oncology, Vol.176, p.S156

09/2023

DOI: https://doi.org/10.1016/j.ygyno.2023.06.155

Metrics

2 Record Views

Details

Title: ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)
Creators: Vicky Makker - Memorial Sloan Kettering Cancer Center
Ignace Vergote
Mansoor Mirza - Rigshospitalet
Robert Coleman - The US Oncology Network
Jose Alejandro Perez Fidalgo - Hospital Clínico Universitario de Valencia
Bradley Monk - Creighton University
Giorgio Valabrega - A. O. Ordine Mauriziano di Torino
Brian Slomovitz - Florida International University
Toon van Gorp
Kathleen Moore - Oklahoma City University
Jalid Sehouli - Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie
David Cibula - Charles University
Tally Levy - Holon Institute of Technology
Gerasimos Aravantinos - National and Kapodistrian University of Athens
Patricia Judson - Karyopharm Therapeutics
Reshma Rangwala - Karyopharm Therapeutics
Xulong Wang - Karyopharm Therapeutics
Publication Details: Gynecologic oncology, Vol.176, p.S156
Identifiers: 991006041271602656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article

ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Related links

Metrics

Details